1. Home
  2. CANF vs PT Comparison

CANF vs PT Comparison

Compare CANF & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • PT
  • Stock Information
  • Founded
  • CANF 1994
  • PT 2012
  • Country
  • CANF Israel
  • PT China
  • Employees
  • CANF N/A
  • PT N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • PT Computer Software: Programming Data Processing
  • Sector
  • CANF Health Care
  • PT Technology
  • Exchange
  • CANF Nasdaq
  • PT Nasdaq
  • Market Cap
  • CANF 14.4M
  • PT 14.8M
  • IPO Year
  • CANF N/A
  • PT 2018
  • Fundamental
  • Price
  • CANF $1.97
  • PT $0.93
  • Analyst Decision
  • CANF Strong Buy
  • PT
  • Analyst Count
  • CANF 2
  • PT 0
  • Target Price
  • CANF $14.00
  • PT N/A
  • AVG Volume (30 Days)
  • CANF 116.8K
  • PT 32.4K
  • Earning Date
  • CANF 11-15-2024
  • PT 04-30-2024
  • Dividend Yield
  • CANF N/A
  • PT N/A
  • EPS Growth
  • CANF N/A
  • PT N/A
  • EPS
  • CANF N/A
  • PT N/A
  • Revenue
  • CANF $667,000.00
  • PT $7,434,458.00
  • Revenue This Year
  • CANF $356.93
  • PT N/A
  • Revenue Next Year
  • CANF N/A
  • PT N/A
  • P/E Ratio
  • CANF N/A
  • PT N/A
  • Revenue Growth
  • CANF N/A
  • PT N/A
  • 52 Week Low
  • CANF $1.81
  • PT $0.71
  • 52 Week High
  • CANF $4.69
  • PT $1.38
  • Technical
  • Relative Strength Index (RSI)
  • CANF 35.55
  • PT 39.94
  • Support Level
  • CANF $1.87
  • PT $0.76
  • Resistance Level
  • CANF $2.04
  • PT $1.12
  • Average True Range (ATR)
  • CANF 0.15
  • PT 0.09
  • MACD
  • CANF 0.00
  • PT -0.01
  • Stochastic Oscillator
  • CANF 18.18
  • PT 45.83

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees also by providing financing for these borrowers and earn installment service fees, They earn wealth management services fees and commission on financial products.

Share on Social Networks: